Fig. 7
Effects of QR-KLU on vascular normalization of subcutaneous Hepa1–6 liver tumors in mice (n = 6). (A) Representative immunofluorescence images of the hypoxia probe pimonidazole (scale bar = 20 μm; pimonidazole+: red; nucleus: blue). (B) Immunohistochemistry results of VEGF expression in subcutaneous Hepa1–6 liver tumors in mice treated with PBS, KLU, QR-KLU, anti-PD-1, and QR-KLU + anti-PD-1 (scale bar = 50 μm). (C) Representative immunofluorescence double-staining images of α-SMA and CD31 in subcutaneous Hepa1–6 liver tumors in mice treated with PBS, KLU, QR-KLU, anti-PD-1, and QR-KLU + anti-PD-1 (scale bar = 20 μm; α-SMA + pericytes: green; CD31 + endothelial cells: red; nucleus: blue). α-SMA, α-Smooth muscle actin; CD31; PBS, phosphate-buffered saline; PPD-1 programmed cell death receptor-1, QR-KLU peptide (QR)–drug (KLU) conjugate, VEGF vascular endothelial growth factor.
